Abstract
Purpose
There is a paucity of data regarding dalbavancin use in patients with a vancomycin
allergy because of potential cross-reactivity between the 2 glycopeptide antibiotics.
Methods
A retrospective medical record review was performed between February 2016 and February
2021 in patients with a listed vancomycin allergy who received dalbavancin as an outpatient
infusion and had a listed vancomycin allergy in the electronic health record.
Findings
There were 559 unique patients during the study period who received dalbavancin as
an outpatient infusion, 10 of whom had a documented vancomycin allergy in the electronic
health record. Four of the 10 patients had a history of a type I IgE-mediated reaction
to vancomycin, 1 patient reported delayed rash, 2 patients reported a vancomycin infusion
reaction, 2 patients reported acute kidney injury, and 1 patient reported intolerance
with general malaise. All 10 patients received at least 1 dose of dalbavancin with
no reported adverse events.
Implications
This case series displays that all patients who received dalbavancin tolerated the
infusion well with no adverse events reported. Dalbavancin may be a viable option
for patients with a listed vancomycin allergy.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Dalvance (dalbavancin) [prescribing information].Allergan USA, Inc., Madison, NJ2021 (Accessed 22 Apr 2022)
- Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.Drug Des Devel Ther. 2021; 15: 3349-3378
- Glycopeptides in clinical development: pharmacological profile and clinical perspectives.Curr Opin Pharmacol. 2004; 4: 471-478
- Graded dalbavancin challenge in a patient with severe vancomycin hypersensitivity reaction.Clin Infect Dis. 2020; 70: 1230-1232
- Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype.J Allergy Clin Immunol. 2021; 147: 403-405
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.Clin Infect Dis. 2020; 71: 1361-1364
- Transitioning from guideline approval to practical implementation of AUC-based monitoring of vancomycin.Am J Health Syst Pharm. 2021; 78: 1270-1272
- Orbactiv (oritavancin) [prescribing information].Melinta Therapeutics, Inc., 2019 (Accessed April 22, 2022)
- A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection.Clin Infect Dis. 2016; 62: 545-551
- Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A*32:01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype.J Allergy Clin Immunol. 2021; 147: 403-405
- Drug allergy: an updated practice parameter.Ann Allergy Asthma Immunol. 2010; 105: 259-273
- Evaluation of dalbavancin on length of stay in acute bacterial skin and structure infections.J Am Coll Clin Pharm. 2019; 2: 477-481
- Financial analysis of dalbavancin for acute bacterial skin and skin structure infections for self-pay patients.Infect Dis Ther. 2020; 9: 1043-1053
- Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care.Pharmacy. 2021; 10: 1
Article info
Publication history
Published online: December 01, 2022
Accepted:
November 15,
2022
Identification
Copyright
© 2022 Elsevier Inc.
